Home
Login
Help
Search this site:
Registered Trials
By recruitment status
By sponsor
By registration date
Advanced search for trials
Registration process
To register a trial
Sponsor registration form
RPCEC trial registration Data Set
To update a registered trial
To disclosure the results of registered trial
Home
List all revisions
View
The revisions let you track differences between multiple versions of a post.
Curmeric- Safety-Community-Quarantine-COVID-19
Updated by CEADEN on 24/03/2023 - 7:18am
Legend
Added
Changed
Deleted
General information
Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.
Scientific title:
Safety study of the natural product Curmeric in a quarantined community in primary care due to possible cases of COVID-19.
Secondary indentifying numbers:
Not applicable
Issuing authority of the secondary identifying numbers:
Not applicable
Primary sponsor:
Center for Technological Applications and Nuclear Development (CEADEN)
Secondary sponsor:
General Calixto Garcia University Hospital
Source(s) of monetary or material support:
Center for Technological Applications and Nuclear Development (CEADEN) University Hospital General Calixto Garcia, Ministry of Public Health
Authorization for beginning
Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.
Regulatory instance to authorize the initiation of the study:
Only approved by Ethics Committees
Principal investigator
Section to complete information about Email address, telephone number and postal address of the Principal Investigator.
First name:
Leticia
Last name:
Borrero Torres
Medical Specialty :
Specialist I grade Medicine General Integrative
Affiliation:
Polyclinic Rampa
Postal address:
Street 17th number 261 between entre J and I. Vedado. Revolution Square Municipality.
City:
Havana
Country:
Cuba
Zip Code:
10400
Telephone:
+53-78352724
Email address:
prampa@infomed.sld.cu
Clinical sites to participate
Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.
Countries of recruitment:
Cuba
Clinical sites:
Not applicable
Recruitment status
Section to complete information about the recruitment status and the date of first enrolment subject
Recruitment status:
Complete
Date of first enrollment:
21/09/2020
Health condition and Intervention
Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
COVID-19
Health condition(s) code:
Disease Prevention
Coronavirus Infections
SARS Virus
Coronaviridae Infections
Nidovirales Infections
Betacoronavirus
Health condition keyword:
COVID-19
SARS-CoV2
Intervention(s):
Curmeric. Natural product that contains extracts of Curcuma longa -in intellectual property process- (oral) 4mL gargle / mouthwash after the main meals for 1 month.
Intervention code:
Curcuma
Administration, Oral
Plant Extracts
Intervention keyword:
mouthwashes, gargles
Outcomes and Timepoint
Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
Adverse Events-AE (Occurrence of AE (Yes, No); Type of event (name of AE); Intensity of AE (Mild, Moderate, Severe); Result (Recovered, Not recovered, Recovered with sequelae, Death); Required treatment (Yes, No)). Measurement time: 1 month
Key secondary outcomes:
Not applicable
Selection criterias
Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Gender:
Male/Female
Minimum age:
5 years
Maximum age:
85 years
Inclusion criteria:
All the inhabitants of the building in quarantine because of COVID-19 in primary health care.
Exclusion criteria:
Known allergy to Turmeric.
Type of population:
Children/Adults
Type of participant:
Healthy volunteers
Study design
Section to complete information about the characteristics of the study design.
Type study:
Observational
Purpose:
Prevention
Allocation:
N/A: single arm study
Masking:
Open
Control group:
Uncontrolled
Study design:
Single group
Phase:
N/A
Target sample size:
186
Contact for public queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status
First Name:
Tania
Last Name:
Valdes Gonzalez
Specialty:
Pharmaceutical Sciences, PhD
Affiliation:
Center for Technological Applications and Nuclear Development (CEADEN)
Postal Address:
Street 30th and 5ta Avenue. Playa
City:
Havana
Country:
Cuba
Zip Code:
11300
Telephone:
+53-72021518
Email :
taniajapon@gmail.com
taniavaldes@infomed.sld.cu
Contact for scientific queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.
First Name:
Tania
Last Name:
Valdes Gonzalez
Specialty:
Pharmaceutical Sciences, PhD
Affiliation:
Center for Technological Applications and Nuclear Development (CEADEN)
Postal Address:
Street 30th and 5ta avenue. Playa
City:
Havana
Country:
Cuba
Zip Code:
11300
Telephone:
+53-72021518
Email :
taniajapon@gmail.com
taniavaldes@infomed.sld.cu
Data Sharing
Section to complete the data related to the data sharing plan.
Data sharing plan:
No
Research Ethics Committees
Section to complete the data related to the review ethics committees.
Name of Research Ethics Committees:
General Calixto Garcia University Hospital
Status of evaluation:
Approved
Status of evaluation date of Ethic Committee:
02/09/2020
Postal address of Ethic Committee :
Ave. Universidad and street J. Plaza de la Revolución. Havana. C.P:10400, Cuba
Telephone:
+53-78382171
Email:
secdircg@infomed.sld.cu
About study completion
Section to complete the data related to the study completion.
Final enrolment number:
186
Study completion date:
21/10/2020
Date of available results:
01/03/2021
Date of first publication:
01/04/2021
Registration and Update
Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).
Primary registry:
RPCEC
Unique ID number:
RPCEC00000350
Date of Registration in Primary Registry:
22/01/2021
Record Verification Date:
2021/01/25
Next update date:
2022/01/25
Link to the spanish version:
Click here
About the RPCEC
Structure and governance
Policy
Publications
Awards
Communications
News
Useful resources
Fundamentals of the registry
References of clinical trials
Cuban regulations
Other registries
International Clinical Trials Registry Platform